PubMed Health⌕ Search

Biomedical subjects

C Angermann

Publications and source records attributed to C Angermann.

25 records · Page 2Linked to original sources
PubMed1983

[Comparative studies on the cardiodepressant effect of disopyramide, mexiletine and propafenon].

The effect of clinical antiarrhythmic doses of disopyramide (Di), mexiletine (Me), and propafenon (Pr) on cardiac function was studied in 7 normal volunteers by M-mode echocardiography and the extent of functional changes caused by the three drugs was compared. For each of the substances echocardiographic parameters of left ventricular function were determined before injection, 5-25 min. after an intravenous administration (Di 2.0 mg/kg, Me 3.0 mg/kg, Pr 1.5 mg/kg) at intervals of 5 min., and after 3 days of oral therapy (Di 4 X 200 mg/day, Me 4 X 200 mg/day, Pr 3 X 300 mg/day). Di, Me, and Pr each showed significant negative inotropic activity, though of varying degree. For each drug the effect was more pronounced after intravenous administration than under oral therapy. Maximum decreases in myocardial contraction occurred 5-15 min. after termination of injection, with an increase in endsystolic diameter (Di 30.3%, Me 13.6%, Pr 9.7%), no change in preejection diameter, and a reduction in the percentage and velocity of mean circumferential fiber shortening and systolic ventricular wall thickness (Di 18.1%-45.1%, Me 9.6%-23.7%, Pr 11.8%-16.7%). While the cardiodepressant activity of orally administered Di, Me and Pr did not statistically differ, for the first 20 min. after intravenous administration Di exhibited a marked negative inotropic effect that was significantly greater than those of Me and Pr. In view of the considerable hemodynamic side effects of Di, Me, and Pr observed in this study, the benefit to risk ratio must be evaluated carefully and individually before commencement of antiarrhythmic therapy. Because of its acute and pronounced cardiodepressant activity, intravenous Di should be used with particular caution; a dose reduction and slow injection are recommended in patients with left ventricular dysfunction.

Adult↗
PubMed1981

[The effect of disopyramide of left ventricular function: an echocardiographic study of the extent and time course (author's transl)].

Seven healthy volunteers were evaluated for changes in left ventricular function after a therapeutic intravenous dose of Disopyramide (2 mg/kg, maximum 150 mg given over 5 min) and, subsequently, under oral maintenance therapy (200 mg every 6 h for 3 days). Parameters of left ventricular function were determined by Echocardiography. Measurements were taken before injection, 5--25 min after intravenous Disopyramide in intervals of 5 min and 120 min after the last oral dose of the drug. Peak changes occurred 5 min after termination of injection and included increases in mean arterial pressure (10%), heart rate (22%) and endsystolic ventricular diameter (30%) and decreases in percentage (43%) and mean velocity (36%) of diameter shortening, decreases of systolic thickness and percentage of thickening of left posterior wall (27 and 43% respectively) and of interventricular septum (15 and 22% respectively) as well as a decrease of the relative thickness of left ventricular wall (40%) and of left posterior (36%) and septal (39%) amplitude. After 20 min changes in all parameters were significantly less than 5 min after injection but still significantly greater than under oral maintenance therapy. After 25 min measurements differed from those under oral Disopyramide only slightly. At both times, however, all parameters were significantly different from control values. Thus, Disopyramide given intravenously and orally in therapeutic dosage is a potent myocardial depressant in man. As the acute negative inotropic effect of intravenous Disopyramide might be of clinical importance in patients with decreased myocardial function a slow injection over 15--20 min and a dose reduction is recommended in these cases.

Adult↗
PubMedDate not supplied

Antimyosin monoclonal antibodies for early detection of cardiac allograft rejection.

Sixty-eight indium 111-labeled antimyosin Fab-DTPA imaging studies (0.5 mg intravenously with a radioactivity of 65 to 75 MBq) were executed on 37 of 116 patients undergoing heart transplantation to assess diagnostic accuracy and clinical utility. As controls, 21 patients with cardiomyopathy (n = 8), unstable angina (n = 9), and myocardial infarction (n = 4) were selected. After 48 hours, single photon emission computed tomographic images were evaluated visually, and heart/lung ratios were measured, using the "region of interest" technique. They were compared with echocardiographic and endomyocardial biopsy results. In 40 studies a heart/lung ratio less than or equal to 1.6 corresponded to a negative biopsy result in 98% (40/41). Echocardiography enabled correct identification of 95% of the patients with normal biopsy findings. In 91% (22/24) a positive biopsy finding correlated with a heart/lung ratio greater than 1.6 including 20 mild rejections, but in only 64%, with an increase in wall thickness and/or decrease of fractional diameter shortening seen on echocardiogram. In addition, the various stages of rejection episodes determined the amount of the heart-lung ratio. There was a significant relationship between the histologic findings and the antimyosin uptake. In 13 patients a second investigation was performed after rejection therapy. All patients had a negative biopsy result, and the heart/lung ratio decreased to normal ranges (less than or equal to 1.6). Five antimyosin antibody studies were excluded, as in these cases, negative uptake results were found during rejection therapy with high-dose steroids. The overall sensitivity was calculated at 93% and the specificity at 98%.(ABSTRACT TRUNCATED AT 250 WORDS)

Antibodies, Monoclonal↗